Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02868268 · ClinicalTrials.gov registry record
Neuroblastoma Precision Trial
A clinical trial of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- Active
- Registry status
- 93
- Enrollment target
- 11
- Study locations
NCT02868268: Active study of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
NCT02868268 is a study of Neuroblastoma that is active but no longer recruiting, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 93 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (61% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02868268, a study of Neuroblastoma, is active but no longer recruiting, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- ACTIVE NOT RECRUITING
- Registry status
- 93 participants
- Enrollment target
- 11
- Study locations
Study Summary
This proposal sets forth the platform for a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy (NANT) consortium. The plan is to utilize NANT's established multi-institutional infrastructure and Translational Genomics Research Institute GEM sequencing platform for acquisition and gene panel sequencing of relapsed biological specimens in relapsed/refractory neuroblastoma (rNB) including those obtained from the bone, bone marrow or soft tissue. Our primary aim is to identify subgroups of rNB patients who have potentially targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor-associated macrophage infiltration and/or programmed death ligand \[PD-L1\] expression) biomarkers in rNB. Additional potential novel biomarkers will also be evaluated and reported in this cohort of patients.
Primary Outcome
Archival or biopsied tumor specimens undergo gene panel sequencing and/or immunohistochemistry and a list of all genetic/immunologic alterations are identified. Was an actionable genetic alteration identified and were any of these alterations within 4 NBL specific subgroups (ALK, MAPK, Metabolic, Immune reactive) or outside of the 4 NBL specific subgroups.
Conditions Studied
Interventions
- OTHER Gene panel sequencing of tumor specimens
Study Locations (11)
California
- Children's Hospital Los Angeles - Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Colorado
- Children Hospital of Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta - Atlanta
Illinois
- Children's Memorial Hospital - Chicago - Chicago
Massachusetts
- Childrens Hospital Boston, Dana-Farber Cancer Institute. - Boston
Michigan
- C.S Mott Children's Hospital - Ann Arbor
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2016-08-22 |
| Est. Completion | 2026-12 |
What the registry record for NCT02868268 still lists
NCT02868268 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Gene panel sequencing of tumor specimens is the first listed.
NCT02868268 lists 11 locations in 10 states (California, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT02868268 about?
NCT02868268 is a clinical study titled "Neuroblastoma Precision Trial". This proposal sets forth the platform for a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy (NANT) consortium. The plan is to utilize NANT's established multi-institutional infrastructure and Translational Genomics Research Institute GEM sequencing platform for ...
What is the current status of trial NCT02868268?
This trial is currently active not recruiting. The enrollment target is 93 participants. The study started on 2016-08-22. Estimated completion is 2026-12.
What conditions does trial NCT02868268 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT02868268?
The interventions under investigation include: Gene panel sequencing of tumor specimens (OTHER).
Who is sponsoring clinical trial NCT02868268?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02868268 being conducted?
This trial has 11 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02868268's enrollment target sits among peer trials
93 32nd of 94 higher than 62 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Neuroblastoma Biology Study
RECRUITING
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05674175 · 93 participants · Phase 1
Co-administration of CART22-65s and huCART19 for B-ALL
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI